InsidersTradesSigma
Follow the Provention Bio, Inc. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Provention Bio, Inc. has logged 23 reports. The latest transaction was filed on 28 April 2023 (U). Among the most active insiders: Leon Francisco. All data is accessible without an account.
23
Insider Decl.
n/a
Thresholds
€87,730
3 ops.
Buy Volume
€26m
2 ops.
Sell Volume
46Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 April 2023
Declarations23 total
15,567,497 sharesCommon StockSEC:0001062993-23-009669:0
7,500 sharesCommon StockSEC:0001493152-23-013919:0
10,000 sharesCommon StockSEC:0001493152-23-013910:0
70,000 sharesCommon StockSEC:0001493152-23-013906:0
2,570,050 sharesCommon StockSEC:0001493152-23-013916:0
73,000 sharesCommon StockSEC:0001493152-23-013907:0
202,314 shares0Common StockSEC:0001062993-23-009486:0
8,879,023 shares@ US$6.0064.8% of flowCommon StockSEC:0001062993-23-009310:0
10,000 shares0Common StockSEC:0001493152-23-012387:0
1,500,000 shares0Common StockSEC:0001493152-23-012403:0
3,000,000 shares0Common StockSEC:0001062993-23-008724:0
50,000 shares@ US$2.5053.7% of flowCommon StockSEC:0001493152-23-005076:0
4,500 shares@ US$10.0012100.0% of flowCommon StockSEC:0001493152-23-005078:0
50,000 shares@ US$2.5016.3% of flowCommon StockSEC:0001493152-23-005080:0
24,015 shares@ US$2.507.8% of flowCommon StockSEC:0001493152-23-002085:0
24,165 shares@ US$2.5025.8% of flowCommon StockSEC:0001493152-23-002086:0
3,000,000 shares@ US$9.4035.2% of flowCommon StockSEC:0001062993-23-001185:0
187,000 shares@ US$2.5061.8% of flowCommon StockSEC:0001493152-22-037133:0
10,674 shares@ US$2.503.5% of flowCommon StockSEC:0001493152-22-036789:0
1,568 shares@ US$2.500.5% of flowCommon StockSEC:0001493152-22-036596:0
5,201 shares@ US$6.49250.0% of flowCommon StockSEC:0001493152-21-030639:0
Canonical exit: 3 Mar 2022 (T+90)
3,750 shares@ US$6.66450.0% of flowCommon StockSEC:0001493152-21-030245:0
Canonical exit: 28 Feb 2022 (T+90)
5,550 shares@ US$7.24150.0% of flowCommon StockSEC:0001493152-21-030027:0
Canonical exit: 22 Feb 2022 (T+90)
23 of 23 declarations
关于 Provention Bio, Inc.
Provention Bio, Inc.是一家总部位于美国的临床阶段生物制药公司，专注于干预和预防免疫介导疾病，尤其侧重于1型糖尿病。该公司于2016年在特拉华州注册成立，主要运营基地位于美国新泽西州雷德班克。对于法国、比利时和瑞士的投资者而言，Provention Bio代表了一种经典的、高风险、高催化剂的生物技术公司形象：估值主要取决于临床开发进展、监管里程碑和战略交易结果，而非成熟的商业规模。在被收购之前，该公司在美国纳斯达克市场上市，这使其明确属于以增长为导向的生物技术公司范畴，这类公司的投资者情绪对试验数据和FDA决策高度敏感。([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315222030280/R7.htm?utm_source=openai)) 其旗舰资产是TZIELD (teplizumab-mzwv)，这是一种同类首创的抗CD3疗法，旨在延缓特定高风险患者1型糖尿病的发生。该资产使Provention Bio拥有了明确差异化的市场地位：该公司并非在拥挤的对症治疗市场中竞争，而是针对自身免疫疾病进展的早期干预。这种对疾病干预的关注是公司身份的核心，并帮助其与更广泛的免疫学或糖尿病开发商区分开来。Provention还在免疫介导和自身免疫适应症方面开展了其他项目，巩固了其作为一家以科学为主导的生物技术平台定位，该平台围绕预防而非传统的慢性疾病管理而建立。([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315222030280/R7.htm?utm_source=openai)) 从竞争角度来看，Provention Bio的优势在于其狭窄但可能具有开创性意义的治疗理念。公司的差异化源于拥有一项具有重要临床和战略吸引力的同类首创资产，而非收入来源的广度或地域覆盖范围。这也意味着集中风险很高：少数项目对企业价值具有过大的影响，这对于处于该阶段的纳斯达克上市公司来说是典型的。其地理足迹主要在美国，在被收购之前没有广泛的全球商业基础设施的迹象。([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315222030280/R7.htm?utm_source=openai)) 最近最重要的公司事件是赛诺菲（Sanofi）对Provention Bio的收购。2023年3月13日，赛诺菲宣布以每股25.00美元的现金协议收购Provention Bio，股权价值约为2.8 billion美元。该交易于2023年4月27日完成，Provention Bio普通股于同日停止在纳斯达克交易。因此，Provention Bio不再是一家独立上市公司；如今，它最好被理解为一项战略收购，将TZIELD纳入赛诺菲的产品组合。对于查阅历史SEC Form 4内幕交易活动的投资者而言，这意味着Provention Bio应被视为一家已退市的发行人，而非活跃的公开股票。([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315223007347/ex99-1.htm?utm_source=openai))
